Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
4/6-8
Plasma Protein Binding %
27
Volume Of Distribution L/Kg
6-7
Dose For Normal Renal Function
75-375 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
75% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med. 1994; 97: 13S-23S. [PMID: 7992822] / Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm. 1994; 51: 3033-46. [PMID: 7856622] / Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995; 49: 280-94. [PMID: 7729333] / Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother. 1995; 29: 387-95. [PMID: 7633018] / Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995; 56 Suppl 6: 12-21. [PMID: 7649968] / Scott MA, Shelton PS, Gattis W. Therapeutic options for treating major depression, and the role of venlafaxine. Pharmacotherapy. 1996; 16: 352-65. [PMID: 8726593]